SCHEMBL5033608

SCHEMBL5033608

N#CC[C@@H]1C[C@H](NC(=O)O)CC[C@@H]1N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.38
RORC P51449 1/20 0.36
POLB P06746 2/20 0.34
ATM Q13315 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
EPHX2 P34913 1/20 0.34
CTSL P07711 2/20 0.34
CTSK P43235 2/20 0.34
CTSS P25774 1/20 0.34
MFN2 O95140 1/20 0.34
USP30 Q70CQ3 3/20 0.33
MAOA P21397 1/20 0.33
HPGD P15428 1/20 0.33
BLM P54132 1/20 0.33
CTSB P07858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5033614 1.00 PTGES (0.38) PTGESRORCPOLBATMMEN1
SCHEMBL5029544 0.85 PTGES (0.39) PTGESMEN1KMT2AEPHX2MFN2
SCHEMBL5029551 0.85 PTGES (0.39) PTGESMEN1KMT2AEPHX2MFN2
SCHEMBL5031958 0.78 ALDH1A1 (0.36) RORCMEN1KMT2AMAOAALDH1A1
SCHEMBL17802165 0.73 YTHDC1 (0.48) PTGESMEN1KMT2AEPHX2HPGD
SCHEMBL17802164 0.73 YTHDC1 (0.48) PTGESMEN1KMT2AEPHX2HPGD
SCHEMBL5029381 0.72 SLC6A4 (0.38) RORCTSHR
SCHEMBL17007365 0.68 SLC18A3 (0.42) PTGESMEN1KMT2AEPHX2HPGD
SCHEMBL19715190 0.68 MFN2 (0.42) KMT2AEPHX2MFN2HPGDALDH1A1
SCHEMBL17440250 0.67 CTSD (0.40) POLBATMMEN1KMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 PTGES 669/4885RORC 1553/4885POLB 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.